Global Addison's disease therapeutics market to be worth $131.6 million

The global Addison's disease therapeutics market has been forecast to increase at a compound annual growth rate (CAGR) of 10.8% through to 2019, to be worth a market value of $131.6 million.

This comes after recording a market value of $57.9m in 2011, having increased at a CAGR of 9.7% during 2006-2011.

Addison's disease is a rare, chronic endocrine disorder in which theadrenal glands do not produce sufficient steroid hormones (glucocorticoids and often mineralocorticoids).

The high growth recorded in the Addison's disease therapeutics market during 2006-2011 can be primarily attributed to increasing prevalence and awareness among patients and physicians of the disease.

The market is expected to continue to increase at a high rate through to 2019, due to the expected launch of Plenadren (hydrocortisone), a modified release formulation of hydrocortisone at a higher price than the currently available glucocorticoid drugs. It will also increase patient compliance due to its once daily dosing schedule.

Competition in the Addison's disease therapeutics market is currently strong. The market is dominated by generic drugs such as hydrocortisone, cortisone, prednisone, dexamethasone and fludrocortisones, all of which are marketed by a number of different pharmaceutical companies as their patent exclusivity has long since expired.

This means that pharmaceutical companies are forced to price their products competitively, ultimately resulting in strong competition.

For more information on the global Addison's disease therapeutics market, see the latest research: Global Addison's Disease Therapeutics Market Report

Follow us on Twitter @CandMResearch